Inventor · disambiguated record
Dana L. Johnson
Also filed as: JOHNSON DANA · JOHNSON DANA L
19 granted patents·7 pending applications·903 citations·filing 1995–2011
94Inventor score
Files withJANSSEN PHARMACEUTICA NV6SCRIPPS RESEARCH INST4ZHANG XUQING3BAUMANN CHRISTIAN A2ORTHO MCNEIL PHARM INC2
Top patents by PatentIndex Score
26 records- 0197US5773569ACompounds and peptides that bind to the erythropoietin receptorAFFYMAX TECH NV·Filed 1995·Granted Jun 30, 1998·416 cites·8 claims
- 0296US5767078AAgonist peptide dimersFiled 1995·Granted Jun 16, 1998·288 cites·9 claims
- 0393US7795279B2Method of inhibiting FLT3 kinaseJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Sep 14, 2010·30 cites·2 claims
- 0492US8030305B2Triazolopyridazines as kinase modulatorsJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Oct 4, 2011·24 cites·18 claims
- 0589US8173654B2Triazolopyridazine compoundsLU TIANBAO·Filed 2008·Granted May 8, 2012·21 cites·15 claims
- 0688US5835382ASmall molecule mimetics of erythropoietinSCRIPPS RESEARCH INST·Filed 1996·Granted Nov 10, 1998·64 cites·6 claims
- 0777US7662824B2Acylhydrazones as kinase modulatorsJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Feb 16, 2010·2 cites·12 claims
- 0875US7563781B2Triazolopyrimidine derivativesJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Jul 21, 2009·2 cites·2 claims
- 0973US7259146B2Neuroprotective peptidesORTHO MCNEIL PHARM INC·Filed 2001·Granted Aug 21, 2007·3 cites·4 claims
- 1072US6221608B1Methods for identifying erythropoietin receptor binding proteinORTHO PHARMA CORP·Filed 1997·Granted Apr 24, 2001·46 cites·1 claims
- 1169US7196110B2N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disordersJANSSEN PHAMACEUTICA N V·Filed 2003·Granted Mar 27, 2007·6 cites·37 claims
- 1266US8557847B2Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitorBAUMANN CHRISTIAN ANDREW·Filed 2009·Granted Oct 15, 2013·0 cites·15 claims
- 1366US7272508B2Small molecule mimetics of erythropoietinSCRIPPS RESEARCH INST·Filed 2005·Granted Sep 18, 2007·1 cites·2 claims
- 1466US2010250600A1Small Molecule Mimetics of ErythropoietinSCRIPPS RESEARCH INST·Filed 2009·Application pending·0 cites
- 1556US7816390B2N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2008·Granted Oct 19, 2010·0 cites·2 claims
- 1656US7795440B2N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disordersJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Sep 14, 2010·0 cites·2 claims
- 1755US2009119019A1Small Molecule Mimetics of ErythropoietinSCRIPPS RESEARCH INST·Filed 2007·Application pending·0 cites
- 1854US2009170759A1Neuroprotective peptidesSMITH-SWINTOSKY VIRGINIA·Filed 2007·Application pending·0 cites
- 1952US2007004660A1Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and AlkylquinazolinesBAUMANN CHRISTIAN A·Filed 2006·Application pending·0 cites
- 2050US8450304B24-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2ZHANG XUQING·Filed 2009·Granted May 28, 2013·0 cites·25 claims
- 2150US2006281788A1Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitorBAUMANN CHRISTIAN A·Filed 2006·Application pending·0 cites
- 2246US7070938B2Method to detect modulators of VEGF kinase domainORTHO MCNEIL PHARM INC·Filed 2001·Granted Jul 4, 2006·0 cites·2 claims
- 2345US8513229B24-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2ZHANG XUQING·Filed 2011·Granted Aug 20, 2013·0 cites·13 claims
- 2444US2005130910A1Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targetsFiled 2004·Application pending·0 cites
- 2539US2010267689A14-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2ZHANG XUQING·Filed 2010·Application pending·0 cites
- 2636US8071768B2Alkylquinoline and alkylquinazoline kinase modulatorsBAINDUR NAND·Filed 2006·Granted Dec 6, 2011·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Dana L. Johnson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →